Unlocking the Potential of LOC644936: A Promising Drug Target and Biomarker
Unlocking the Potential of LOC644936: A Promising Drug Target and Biomarker
LOC644936 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the actin-associated protein 2 (AAP2) gene, which is involved in a wide range of cellular processes, including cytoskeletal organization, cell signaling, and tissue mechanics. This gene has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LOC644936 has become an attractive target for drug development.
The actin-associated protein 2 (AAP2) gene
AAP2 is a protein that is involved in the regulation of actin filament organization and dynamics. It plays a critical role in the cytoskeleton, which is a complex network of filaments and fibers that provides structural support to the cell and helps maintain cell shape. AAP2 is also involved in cell signaling, specifically in the regulation of the actin-associated protein 3 (AAP3), which is a protein that is involved in cell adhesion and migration.
The LOC644936 gene
LOC644936 is a non-coding RNA molecule that is highly conserved across various species, including humans. It is located on chromosome 6 and has a length of approximately 200 nucleotides. LOC644936 is regulated by various factors, including microRNA (miRNA) and non-coding RNA (ncRNA) interactions.
In addition to its role in regulating AAP2, LOC644936 has also been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and cellular signaling. It has been shown to play a critical role in the regulation of cell cycle progression, specifically in the G1 phase, which is a critical phase of cell growth where the cell prepares for cell division.
As a drug target, LOC644936 has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LOC644936 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting LOC644936 may be an effective way to treat these diseases.
In addition to its potential as a drug target, LOC644936 has also been identified as a potential biomarker. The expression of LOC644936 has been shown to be regulated by various factors, includingmiRNA and ncRNA interactions. This suggests that LOC644936 may be a useful biomarker for the diagnosis and monitoring of various diseases.
The future of LOC644936
The identification of LOC644936 as a potential drug target and biomarker has significant implications for the future of medical research. LOC644936 has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
For example, LOC644936 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. Targeting LOC644936 may be an effective way to treat these diseases, as doable drug treatments can be developed to specifically target this gene.
In addition, LOC644936 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases. The expression of LOC644936 has been shown to be regulated by various factors, includingmiRNA and ncRNA interactions. This suggests that LOC644936 may be a useful biomarker for
Protein Name: Actin Beta Pseudogene
The "LOC644936 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC644936 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC645086 | LOC645181 | LOC645188 | LOC645266 | LOC645468 | LOC645503 | LOC645967 | LOC646044 | LOC646214 | LOC646358 | LOC646471 | LOC646674 | LOC646736 | LOC646762 | LOC646813 | LOC646836 | LOC646853 | LOC646903 | LOC646934 | LOC646970 | LOC647115 | LOC647132 | LOC647481 | LOC649133 | LOC650157 | LOC650226 | LOC651536 | LOC652276 | LOC652608 | LOC653303 | LOC653503 | LOC653513 | LOC653631 | LOC653653 | LOC653698 | LOC727751 | LOC728024 | LOC728098 | LOC728114 | LOC728138 | LOC728376 | LOC728392 | LOC728417 | LOC728485 | LOC728554 | LOC728660 | LOC728688 | LOC728715 | LOC728739 | LOC728743 | LOC728877 | LOC728989 | LOC729086 | LOC729164 | LOC729173 | LOC729218 | LOC729296 | LOC729444 | LOC729609 | LOC729683 | LOC729732 | LOC729737 | LOC729815 | LOC729870 | LOC729887 | LOC729966 | LOC729973 | LOC730098 | LOC730100 | LOC730101 | LOC730183 | LOC730234 | LOC730338 | LOC730668 | LOC90246 | LOC91450 | LOC93429 | LOC93463 | LOC93622 | LOH12CR2 | Long intergenic non-protein coding RNA 1336 | Long intergenic non-protein coding RNA 205 | Long intergenic non-protein coding RNA 266-4, pseudogene | Long-chain-fatty-acid--CoA ligase | LONP1 | LONP2 | LONRF1 | LONRF2 | LONRF3 | LORICRIN | LOX | LOXHD1 | LOXL1 | LOXL1-AS1 | LOXL2 | LOXL3 | LOXL4 | LPA | LPAL2 | LPAR1
